Clinical Trial Update: Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226) [Phase 2]

View source ↗

Summary

Phase 2 trial update for GB226 in Chinese patients with relapsed/refractory peripheral T cell lymphoma (PTCL).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• GB226

Snippet

Sponsor: Genor Biopharma Co., Ltd. | Conditions: Peripheral T Cell Lymphoma | Phase 2 | Status: UNKNOWN